Beyfortus Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Beyfortus market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as a rising demand for effective infant prophylaxis, greater need for long-acting monoclonal antibodies, heightened global awareness of respiratory diseases, geographic expansion, and an increased focus on infant health.

The expected growth in the forecast period is driven by the growing burden of respiratory syncytial virus (RSV) infections, the increasing medical need for RSV prevention, heightened interest from healthcare providers, stronger influence of health policies, and greater diversity in clinical trials. Key trends in the forecast period include the use of AI in drug development, telemedicine and remote monitoring, advancements in regenerative medicine, wearable technologies and biosensors, and the development of gene editing and CRISPR technology.

The increasing number of RSV cases is expected to drive the growth of the beyfortus market in the coming years. Respiratory syncytial virus (RSV) is a highly contagious virus that primarily affects the respiratory system, leading to conditions such as bronchiolitis and pneumonia, particularly in infants, young children, older adults, and individuals with weakened immune systems. Factors contributing to the rise in RSV cases include delayed exposure due to pandemic restrictions, changes in the virus's seasonality, lower immunity in children, and increased social interactions. Beyfortus helps reduce RSV cases by offering passive immunity through a single-dose monoclonal antibody, nirsevimab, which targets and neutralizes the virus. This prevents severe lower respiratory tract infections in newborns and infants during their first RSV season. For example, the National Library of Medicine reported in June 2024 that between 2021 and 2023, RSV cases increased by 2.4 times compared to the pre-pandemic period, while RSV test volumes saw an 18.9-fold increase. As a result, the rising incidence of RSV is driving the growth of the beyfortus market.

The increasing demand for telehealth services is also expected to propel the beyfortus market forward. Telehealth refers to the remote delivery of healthcare through digital technologies, enabling patients to consult with healthcare providers via video calls, phone calls, or online platforms. The rise in telehealth is driven by a greater need for convenient and accessible healthcare, advances in digital technology, and the need for safer care delivery during and after the COVID-19 pandemic. Beyfortus enhances telehealth services by offering targeted protection against RSV for vulnerable populations, allowing healthcare providers to conduct timely virtual consultations and proactive care management for at-risk individuals, particularly during RSV season. This reduces the need for in-person visits and improves patient outcomes through remote monitoring and tailored treatment plans. For instance, a study by the Office of the Assistant Secretary for Planning and Evaluation found that between 2021 and 2022, telehealth usage ranged from 20.5% to 24.2% of adults, with the highest usage rates among Medicaid and Medicare recipients. Thus, the growing demand for telehealth is boosting the beyfortus market.

A major trend in the beyfortus market is the focus on developing innovative antibody-based treatments, such as human IgG1κ antibodies, which offer high stability, efficient antigen binding, and strong immune activation. Human IgG1κ antibodies are a subtype of the IgG immunoglobulin class, known for their role in immune responses, including antigen binding and immune cell activation. For example, in July 2023, Sanofi SA, in collaboration with AstraZeneca Plc, announced that the Food and Drug Administration (FDA) had approved Beyfortus (nirsevimab-alip). This treatment is recommended for preventing lower respiratory tract disease (LRTD) caused by RSV in newborns and infants during their first RSV season, as well as for children up to 24 months old who remain at risk during their second RSV season. The FDA's approval followed a positive recommendation from the FDA Antimicrobial Drugs Advisory Committee and was supported by an extensive clinical development program, which included three pivotal late-stage trials. These trials showed that a single dose of Beyfortus was highly effective against RSV LRTD, providing protection for up to five months, the typical length of an RSV season. Additionally, Beyfortus was well tolerated, with a favorable and consistent safety profile across all trials.

The key companies operating in the beyfortus market are AstraZeneca plc and Sanofi SA.

North America was the largest region in the beyfortus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in beyfortus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the beyfortus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Beyfortus is a monoclonal antibody medication (nirsevimab) developed to provide passive immunity against respiratory syncytial virus (RSV). It is used to prevent RSV-related lower respiratory tract infections in newborns and infants during their first RSV season, offering long-term protection with just one dose.

The primary uses of beyfortus are RSV prevention and infant care. RSV prevention involves efforts to protect infants from Respiratory Syncytial Virus (RSV), a major cause of severe respiratory illness in young children. It is available through multiple distribution channels, such as hospitals, pharmacies, and public health programs.

The beyfortus market research report is one of a series of new reports that provides beyfortus market statistics, including beyfortus industry global market size, regional shares, competitors with a beyfortus market share, detailed beyfortus market segments, market trends and opportunities, and any further data you may need to thrive in the beyfortus industry. This beyfortus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The beyfortus market consists of sales of vaccines, allergy and over-the-counter medications, oncology drugs and central nervous system drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.